Curettage and packing with polymethylmethacrylate cement is a routine treatment for giant-cell tumour (GCT) of bone. We performed an in vitro evaluation of the cytotoxic effect of a combination of cement and methotrexate, doxorubicin and cisplatin on primary cell cultures of stromal GCT cells obtained from five patients. Cement cylinders containing four different concentrations of each drug were prepared, and the effect of the eluted drugs was examined at three different time intervals.
A giant-cell tumour (GCT) has been described by the World Health Organisation as "an aggressive, potentially malignant lesion."
1 It remains one of "the most obscure and intensively examined" tumours of bone. 1 The three histological components of a GCT are osteoclast-like giant cells which comprise most of the cells, monocytic round cells and spindle-shaped fibroblast-like stromal cells. It is likely that the last represents the neoplastic component of this tumour. 2 Curettage and packing with polymethylmethacrylate (PMMA) is a form of treatment for a GCT 3 because of "its accessibility, low price, few complications and acceptable recurrence rate (9%)". 4 PMMA can also be used as a skeletal drugdelivery system. 5 Several investigators [6] [7] [8] [9] [10] have described the use of bone cement containing antibiotics, and satisfactory results have been reported in the treatment of chronic osteomyelitis and post-operative infections. 11 When chemotherapeutic agents such as doxorubicin, 12 cisplatin 12 and methotrexate 13 are added to PMMA they remain active against different tumours and resist heat polymerisation.
14 The compressive properties of PMMA do not seem to be influenced by the addition of drugs.
15
In this study we investigated the cytotoxic effects of the combination of PMMA and antiblastic drugs including methotrexate, doxorubicin and cisplatin on stromal GCT cells collected from five patients. In addition, in three patients a comparison was made between the cytotoxic effects of these antiblastic drugs eluted from the cement on GCT and intact bone tissue.
Patients and Methods
Per-operative specimens of GCT were taken from five patients on whom routine preoperative histological and radiological confirmation of the diagnosis had been made. Details of the patients are given in Table I . The freshlyharvested surgical specimens were used for primary culture. Also, in three patients, bone graft was taken during the operation and some of this tissue was used for the study.
Informed consent from the patients and ethical approval had been obtained for the study. Cell isolation. The tumour or normal bone tissue was placed in nutritional medium (RPMI-1640; GIBCO, Carlsbad, California) containing antibiotics (100 U/ml of penicillin and 100 μg/ml of streptomycin; Sigma, St Louis, Missouri) and transferred to the cellculture laboratory in the Pasteur Institute of Iran. The tissues were rinsed in phosphatebuffered saline (PBS) (Sigma), transferred to a Petri dish and cut into small pieces < 1 mm in size. These were incubated with 1% collagenase type III (Sigma) diluted in complete medium (RPMI + 10% fetal bovine serum) for five hours at 37º C in a humidified atmosphere with 5% CO 2 . Tumour cells and osteoblastic cells from normal bone were cultured in complete medium at 37°C and 5% CO 2 . The cul-ture medium was renewed twice a week. After four to five passages, the giant cells and monocytes had disappeared from the culture and stromal GCT cells were almost the only remaining cells. A homogenous tumour-cell population was collected for the study after the ninth to 12th passages. Osteoblasts from normal bone were obtained after two or three passages. Immunofluorescent labelling. For immunofluorescence studies, tumour cells from different passages were placed on chamber slides. In the early passages, the fluorescence labelling was performed with anti-CD68 (DAKO, Hamburg, Germany) known as a specific antigen for osteoclast-like giant cells. In later passages, fluorescence labelling with anti-Osteonectin (Zymed, Los Angeles, California) was used to differentiate stromal GCT cells from fibroblasts. The fluorescein isothiocyanate-labelled secondary rabbit anti-mouse antibody (Dako Deutschland GmBH, Hamburg, Germany) was diluted 1:20. Each antibody was incubated for one hour at 37ºC. Emission of fluorescein isothiocyanate was at a wavelength of 495 nm.
Preparation of cement cylinders containing antiblastic drugs. Cylinders of cement were prepared using Simplex P bone cement (Howmedica, Mahwah, New Jersey) which consists of 40 g of PMMA powder including 4 g of barium sulphate and 20 ml of solvent (2.6% of polymerisation accelerator N, N-dimethyl-p-toluidine and 97.4% of methylmethacrylate monomer) with the addition of an antiblastic drug powder containing amethopterin, doxorubicin hydrochloride and cisplatin platinum (II) diammine dichloride (Sigma). The cylinders were 3 mm in diameter, 4 mm in height and weighed 60 mg. Cylinders either contained no added drugs or had four different doses of each drug as follows: 75 μg, 100 μg, 150 μg and 240 μg. We had initially performed a pilot study in which we compared the details of the cylinders to establish their homogeneity and also their equal ability to elute cytotoxic drugs at each concentration. The cylinders were sterilised by gamma radiation and all the tests were carried out 24 hours after their manufacture in order to avoid the adverse effect of heat polymerisation of the cement and to prevent its interference with the effect of the eluted drugs on our results. Cytotoxic assay. In order to test the cytotoxic effect of the drugs which were eluted from the cement, each cylinder was placed in a 96-well plate (Nunc, Roskilde, Denmark). The cylinders containing different concentrations of methotrexate, doxorubicin and cisplatin were placed in the plate in the order shown in Figure 1a . The control wells contained cylinders without either drug or media. For the comparison between the cytotoxic effect of drugs on tumour tissue and bone in the three patients who had a bone graft, only one dose (100 μg) of antiblastic drugs was used. Similarly, another plate (Fig. 1b) with the same design and including only stromal GCT cells and osteoblasts was prepared for each patient. In each well, 2 x 10 3 cells were seeded. The study was repeated three times. For each patient and each time interval two plates (one with cement cylinders and one with cells) were prepared. All the plates were incubated at 37ºC in an atmosphere of 5% CO 2 . A total of 100 μl was collected from each well and added to the corresponding well on the cell plate at days 3, 7 and 14 of the experiment. After incubation for two days, we assessed the proliferation of stromal GCT cells in the presence of eluted cytotoxic drugs using dimethylthiazol diphenyl tetrazolium bromide (MTT). The media were removed from the wells and replaced with 100 μl of a 0.5 mg/ml solution of MTT (Sigma) dissolved in PBS for five hours at 37ºC. The formazan crystals formed were then dissolved by the addition of 100 μl of isopropanol (Sigma) per well. The plates were incubated at 37ºC for ten minutes. The optical density was recorded on a multiwell microplate reader (ICN, Basel, Switzerland) at 570 nm.
Measurement of the elution of antiblastic drugs from the cement cylinders. Cement cylinders with the same characteristics (four different concentrations of the three drugs) were prepared for the release assay and placed in a 96-well plate filled with 100 μl of media. The control wells contained cement cylinders without either drugs or media. The plate was incubated at 37ºC in 5% CO 2 atmosphere. The concentrations of eluted drugs were measured every two days for one month using spectrophotometry (Amersham, Piscataway, New Jersey) at 303 nm for methotrexate, 252 nm for doxorubicin and 300 nm for cisplatin. For each measurement the media were removed from each well and replaced with 100 μl of fresh media. The assay was repeated three times. Statistical analysis. Group differences were assessed using General Linear Models (GLM), adjusting for potential confounders. When these test results were significant, the Tukey multiple-comparison test was performed. A p-value ≤ 0.05 was considered to be statistically significant.
Results
The characterisation of stromal GCT cells. The immunofluorescent study showed that plates containing stromal GCT cells, were positive for anti-Osteonectin labelling and that the control group of fibroblast cells was negative. Also, in the early stages, the GCT specimens were positive for anti-CD68. Elution of cytotoxic drugs. The release of each drug in different concentrations is shown in Figure 2 . At one month the release of all three drugs had almost the same pattern. It was greatest on the first day and decreased dramatically after the third day with a permanent rate of elution being achieved after one week. The eluted drugs correlated with the amount incorporated into the cylinders but this difference decreased with the passage of time and became negligible at the end of the experiment. In addition, the pattern of release remained similar for all four doses of each drug. The amount of drugs eluted for each of the four doses is shown in Table II . The proportion of the amount eluted to the amount incorporated in the cylinders was smallest for the highest concentration (240 μg) and greatest for the lowest concentration (75 μg) except for the methotrexate during the first week, in which the four concentrations had practically the same amount of elution. The mean percentage of drug eluted in the first week was 6.3% for methotrexate, 6.0% for doxorubicin and 6.1% for cisplatin, and at four weeks was 9.3% for methotrexate, 11.0% for doxorubicin and 7.6% for cisplatin. The effect of eluted cytotoxic drugs on stromal GCT cells. In Figure 3 the cytotoxic effect of the drugs on stromal GCT cells in each patient is shown separately. After adjustment for time, there was no significant difference between the two control groups, cells only and cylinders without drugs, (F = 0.16, p = 0.692). Thus the cement was not cytotoxic and did not affect cell survival.
In multivariate analysis, the drug (F = 4.5, p = 0.01), day (F = 5.7, p = 0.001) and dose (F = 105, p < 0.001) were significant predictors of cytotoxicity. The day of assessment
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Osteoblasts (Fig. 1a) was added to the cell plate. The x marked wells contained phosphate buffered saline for inhibiting the edge effect.
was a significant predictor of cell survival after adjustment for the dose of each drug (p < 0.001 in all analyses).
The effect of the drugs on cell survival is shown in Table  III . Although there were no clear differences between the four doses of each drug at day three, cell survival with different doses of drugs began to change at day seven (Fig. 3) and at day 14 there were clear differences between the four doses of each drug. There were no significant differences between the four doses of each drug in the whole experiment after adjustment for day. With increasing 
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Graphs showing the release pattern of the cytotoxic cylinders over one month for a) methotrexate (MTX), b) doxorubicin (DOX) and c) cisplatin (CIS) measured at a specific optical density of 303, 252 and 300 nm, respectively. Four concentrations were used for each drug (1, 240 μg; 2, 150 μg; 3, 100 μg; and 4, 75 μg). time, as the cells proliferated, the therapeutic action of the drugs decreased, but even at the lowest dose of each drug at day 14, there was a considerable cytotoxic effect on stromal GCT cells (45% for doxorubicin, 34% for cisplatin and 31% for methotrexate). Of the three drugs, doxorubicin was clearly the most potent, after adjustment for dose, but this difference was statistically significant only on day seven (F = 12.2, p < 0.001). There was no visible or significant difference between methotrexate and cisplatin.
In post hoc analyses (Tukey), doxorubicin was significantly more effective (p = 0.05) than the others, with the 240 μg dose being significantly more effective (p = 0.05) than the third-placed 100 μg or fourth-placed 75 μg doses. Additionally there were significant differences between the cytotoxic effects of each drug at each concentration on days 3, 7 and 14.
Comparison of the effects of eluted drugs on stromal GCT cells and osteoblasts. A comparison between the effect of eluted drugs on both tissues was made using one dose of each drug (100 μg). The result of cell survival is shown in Table IV . On days 3 and 7, there were no differences between the effects of the drugs on both tissues. These differences became more apparent on day 14, when all the drugs seemed to have a more cytotoxic effect on bone cells. Doxorubicin was the most potent drug for bone tissue also, and there was no significant difference between methotrexate and cisplatin. In multivariate analysis using the general linear model, stromal GCT cells or osteoblasts were not significant predictors of cytotoxicity.
Discussion
Recurrence rates of between 0% and 25% have been reported after the treatment of GCTs by curettage and packing with PMMA. 1, 3, 16 In order to reduce the local recurrence rate various associated local adjuvant treatments such as phenol, alcohol and polymethylmethacrylate, have been proposed. 1 We have examined the effect of eluted methotrexate, doxorubicin and cisplatin from PMMA on the primary culture of GCT cells. The drugs which were chosen are commonly used in the treatment of bone sarcoma, and have been shown to have specific effects on stromal GCT cells, which are thought to be the neoplastic component of the tumour. Some investigators, have mixed cement with cytotoxic drugs and used the combination to reduce the local rate of recurrence of the tumour. Hernigou et al, 13 reported a considerable local concentration of eluted methotrexate from the cement in the treatment of malignant tumours. Greco et al, 12 reported similar findings using doxorubicin and cisplatin, and Kirchen et al 17 described a chemotherapeutic effect of eluted methotrexate on two GCT cell lines. D3  D7  D14  D3  D7  D14  D3  D7  D14  D3  D7  D14  D3  D7 D3  D7  D14  D3  D7  D14  D3  D7  D14  D3  D7  D14  D3  D7 Histograms showing the cytotoxic effect of eluted antiblastic drugs on stromal giant-cell tumours (GCT) cells demonstrated by dimethylthiazol diphenyl tetrazolium bromide assay. The result of cell viability of eluted a) methotrexate (MTX), b) doxorubicin (DOX) and c) cisplatin (CIS), for each patient at day (D) 3, day 7, and day 14 is represented at an optical density of 540 nm. Four different concentrations were used for each drug (1, 240 μg; 2, 150 μg; 3, 100 μg; and 4, 75 μg). In addition, the control groups including cement with no drugs (GCT+cement) and cells only (GCT) are shown.
Fig. 3c
We found a significant difference between the cytotoxic effects of eluted drugs on different days of the study. On day 3, the cytotoxic effect was nearly the same for all four doses of the drug. By day 7 the differences between the four doses had become more apparent and on day 14 they were clear, with 240 μg doses significantly more effective than of doses of 100 μg or 75 μg. As expected, doxorubicin was the most potent drug, but there was no significant difference between methotrexate and cisplatin. The therapeutic effect of the three drugs and the differences between them decreased towards the end of the experiment.
Rosa et al 18 have shown that the cell inhibition induced by cytotoxic drugs eluted from cement was the same after 15 days. The reduced cytotoxic effect in our study could be due either to cell proliferation or to the reduction in the amount of the eluted drugs. We did not examine these two factors separately, but the lowest dose of each drug still had a considerable cytotoxic effect on the last day of the experiment: 45% for doxorubicin, 34% for cisplatin and 31% for methotrexate.
In three patients, a comparison of the cytotoxic effect of the drugs was made between intact bone and stromal GCT cells collected from the same patients. There was no significant difference in the behaviour of the two tissues towards the drugs. However, a slight difference in the growth of the two tissues was detected after 14 days.
The elution of drugs from PMMA remains controversial. Most studies have been performed with antibiotics, and suggest that the formulation 19 and microstructure of the cement, and the amount 20 and combination 21 of the drugs incorporated in the cement could influence the rate of elution. For cytotoxic agents, fewer factors have been studied. As for antibiotics, the formulation of the cement affects the elution 22 and, as far as drug combination is concerned, a mixture of pamidronate and doxorubicin rather than each drug separately and showed a better rate in the combination form. 20 The surface of the cement may also affect elution.
17 Different amounts of elution have been reported. Wasserlauf et al, 22 showed elution of up to 6% for methotrexate, 3.3% for cisplatin and 3.4% for 5-fluorouracil. Kim et al 23 noted a mean elution of methotrexate of 6.1% in the first week and a total of 9.6% for a period of four weeks. Handal et al 24 suggested a method of predicting the amount of the drug released from cement.
In our study, all the drugs had the same pattern of release. It was greatest during the first day and dramatically decreased after the third. A small amount of release continued for one month. This initial rapid release has been previously described. 15, 25 There was a direct relationship between the eluted drugs and the amount incorporated in the cement, but this difference became less apparent towards the end of the experiment and the amount eluted in different doses was practically the same. We found that the proportion of drug eluted to the amount incorporated into cylinders was greatest for the lowest concentration of each drug. This has also been observed by Maccauro et al.
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After four weeks, doxorubicin had the highest rate of elution with a mean of 11% compared with 9.25% for methotrexate and 7.62% for cisplatin.
According to the Developmental Therapeutics Program NCI/NIH the 50 Lethal Concentration (LC50) of methotrexate, doxorubicin and cisplatin are, respectively, 1 x 10 -5 M, 1 x 10 -4.6 M and 1 x 10 -4.3 M. 26 In our experience, the mean amounts of eluted in the lowest and highest doses of each were 1.8 x 10
-5 M to 4.2 x 10 -5 M for methotrexate, 2 x 10 -5 M to 2.8 x 10 -5 M for doxorubicin and 2.8 x 10 -5 M to 3.8 x 10 -5 M for cisplatin. Consequently, the eluted drugs were practically all in the range of the mentioned LC50.
The use of adjuvant cytotoxic drugs in the treatment of a benign tumour may be considered to subject a patient to unnecessary side-effects. A GCT, however, is a potentially malignant lesion with a rate of local recurrence which is higher than that of other benign tumours. 1 Although curettage has been advocated for the treatment of local recurrences, 3 the size of the tumour is often underestimated, leading to incomplete removal. 27 Even in aggressive GCTs the adjacent joint is usually preserved and successful local adjuvant therapy would lead to improved outcome.
Our results show that drugs from PMMA have cytotoxic effects on stromal GCT cells and these effects are related to the concentration of the drugs incorporated into the cement and the interval at which the effect is measured. There were no clear differences between the cytotoxic effects of the four doses of each drug initially. This pattern changed with time, and clear differences were detected at the end of our study, even although there remained considerable cytotoxicity with the lowest dose of each drug. Hence, bearing in mind the fact that low doses of cytotoxic drugs have fewer side-effects, a relatively small dose could lower the rate of recurrence after curettage and packing with PMMA. However, the effect of this adjuvant therapy on GCT and the surrounding bone requires a larger study both in vitro and in vivo before it could be recommended for clinical use. Many other factors such as the blood supply, the site of the tumour, and the kinetic characteristics of drug release from cement could potentially influence the in vivo model and should be considered in further studies.
